newsfilter
← Latest News
GlobeNewswire·

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660; expect to initiate tumor-specific expansion cohorts in the second quarter of 2024 and announce initial clinical data in